Moderna CEO says coronavirus vaccine could be ready by end of year

Moderna CEO says coronavirus vaccine could be ready by end of year
© Getty Images

The CEO of Moderna, one of the biotech companies working to develop a coronavirus vaccine, said on Wednesday that one could be ready to be sent to the Food and Drug Administration (FDA) by the end of this year. 

“It is possible — assuming a best-case scenario and there are many risks that could derail us, obviously — but we could potentially be in a position to file to the FDA toward the end of the year or early next year,” Stéphane Bancel said on Fox Business's “Mornings with Maria."

“Again, it's a best-case scenario,” he emphasized.


Moderna announced this week that early data from a phase one clinical trial showed that people given a potential vaccine generated an immune response similar to one in people who had recovered from the disease. Additionally, company's potential vaccine was successful in preventing the virus from replicating in mice’s lungs in another study, it said.

The company, which is working with the National Institute of Allergy and Infectious Diseases, led by Anthony FauciAnthony FauciTrump hits Biden and Obama in defense of his golfing Biden swipes at Trump: 'Presidency is about a lot more than tweeting from your golf cart' Top New Mexico tourism official says mass gatherings may not be possible for 18 months MORE, will soon begin a phase two trial and said it hopes to begin a phase three trial in July.

Bancel has said that manufacturing of the vaccine could start as early as July, even before trials are complete, through a partnership with the Swiss biotech company Lonza.

"They are allowing us through their infrastructure and their factories to potentially build manufacturing capacity to deliver up to 1 million doses," he said on Wednesday.